Literature DB >> 27900941

The kidney in sickle hemoglobinopathies
.

Medha Airy, Garabed Eknoyan.   

Abstract

With improvements in the care of patients with sickle hemoglobinopathies, sickle cell disease (SCD) has evolved from a disease that was fatal in childhood into one in which most survive past their 5th decade and some into old age. As a result, the renal complications of sickle hemoglobinopathies, which are age dependent, have emerged as a common and serious complication of SCD. Approximately 14 - 18% of mortality in SCD is attributed to chronic kidney disease (CKD), which develops in 1/3 of individuals with SCD and progresses to end-stage renal disease in 4 - 18% of them. Importantly, the presence of CKD increases the risk of the other systemic complications of SCD, with the median survival of SCD estimated at 51 years, declining to 29 years in those with CKD. The obstructive vasculopathy of SCD affects the glomerulus, tubules, and medulla of the kidney. Albuminuria and inability to concentrate the urine precede the onset of renal failure, and, along with other tubular dysfunctions, are early warning signs of sickle cell nephropathy (SCN). This is a review of the historical background SCN, the pathophysiology of the renal lesions, their varied clinical and pathologic manifestations, and available treatment options.
.

Entities:  

Mesh:

Year:  2017        PMID: 27900941     DOI: 10.5414/CN108991

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  7 in total

1.  Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis.

Authors:  Marina Jerebtsova; Santosh L Saraf; Xionghao Lin; Gillian Lee; Elena Afia Adjei; Namita Kumari; Nowah Afangbedji; Rasha Raslan; Charlee McLean; Victor R Gordeuk; Sergei Nekhai
Journal:  Am J Hematol       Date:  2017-11-27       Impact factor: 10.047

2.  Anticoagulation strategies and recurrence of venous thromboembolic events in patients with sickle cell disease: a systematic review and meta-analysis.

Authors:  Nadirah El-Amin; Audra Iness; John W Cyrus; India Sisler; Oliver Karam
Journal:  Ann Hematol       Date:  2022-07-27       Impact factor: 4.030

3.  Urinary Kringle Domain-Containing Protein HGFL: A Validated Biomarker of Early Sickle Cell Anemia-Associated Kidney Disease.

Authors:  Sergei Nekhai; Xionghao Lin; Simran Soni; Ammanuel Taye; Nathan Smith; Nowah Afangbedji; Santosh L Saraf; Victor R Gordeuk; James G Taylor; Marina Jerebtsova
Journal:  Am J Nephrol       Date:  2021-08-10       Impact factor: 4.605

Review 4.  How I diagnose and treat venous thromboembolism in sickle cell disease.

Authors:  Arun S Shet; Ted Wun
Journal:  Blood       Date:  2018-05-15       Impact factor: 22.113

5.  Prevalence of Microalbuminuria in Adult Patients with Sickle Cell Disease in Eastern Saudi Arabia.

Authors:  Ahmed M Alkhunaizi; Adil A Al-Khatti; Mansour A Alkhunaizi
Journal:  Int J Nephrol       Date:  2018-02-27

6.  Nephrology key information for internists.

Authors:  Sohail Abdul Salim; Juan A Medaura; Bharat Malhotra; Vishnu Garla; Shradha Ahuja; Nicki Lawson; Amaleswari Pamarthy; Hardik Sonani; Karthik Kovvuru; Venkataraman Palabindala
Journal:  J Community Hosp Intern Med Perspect       Date:  2017-06-06

7.  Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition.

Authors:  Pamela L Brito; Alisson F Dos Santos; Hanan Chweih; Maria E Favero; Erica M F Gotardo; Juliete A F Silva; Flavia C Leonardo; Carla F Franco-Penteado; Mariana G de Oliveira; Wilson A Ferreira; Bruna C Zaidan; Athanase Billis; Giorgio Baldanzi; Denise A Mashima; Edson Antunes; Sara T Olalla Saad; Fernando F Costa; Nicola Conran
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.